Jim Simons’s Xenon Pharmaceuticals XENE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $17.5M | Buy |
+300,500
| New | +$13.8M | 0.03% | 712 |
|
|
2025
Q4 | – | Sell |
-5,200
| Closed | -$209K | – | 3826 |
|
|
2025
Q3 | $209K | Sell |
5,200
-3,400
| -40% | -$120K | ﹤0.01% | 3123 |
|
|
2025
Q2 | $269K | Sell |
8,600
-146,100
| -94% | -$4.77M | ﹤0.01% | 3076 |
|
|
2025
Q1 | $5.19M | Buy |
154,700
+141,000
| +1,029% | +$5.35M | 0.01% | 1413 |
|
|
2024
Q4 | $537K | Sell |
13,700
-30,300
| -69% | -$1.25M | ﹤0.01% | 2813 |
|
|
2024
Q3 | $1.73M | Sell |
44,000
-48,900
| -53% | -$1.97M | ﹤0.01% | 2116 |
|
|
2024
Q2 | $3.62M | Buy |
92,900
+36,500
| +65% | +$1.46M | 0.01% | 1508 |
|
|
2024
Q1 | $2.43M | Buy |
56,400
+23,800
| +73% | +$1.09M | ﹤0.01% | 1902 |
|
|
2023
Q4 | $1.5M | Buy |
32,600
+10,700
| +49% | +$378K | ﹤0.01% | 2134 |
|
|
2023
Q3 | $748K | Buy |
+21,900
| New | +$819K | ﹤0.01% | 2489 |
|
|
2022
Q2 | – | Sell |
-150,777
| Closed | -$4.61M | – | 4624 |
|
|
2022
Q1 | $4.61M | Sell |
150,777
-230,100
| -60% | -$6.89M | 0.01% | 1659 |
|
|
2021
Q4 | $11.9M | Sell |
380,877
-238,200
| -38% | -$7.12M | 0.01% | 986 |
|
|
2021
Q3 | $9.46M | Sell |
619,077
-38,900
| -6% | -$676K | 0.01% | 1066 |
|
|
2021
Q2 | $12.3M | Sell |
657,977
-35,000
| -5% | -$645K | 0.02% | 1034 |
|
|
2021
Q1 | $12.4M | Sell |
692,977
-77,000
| -10% | -$1.31M | 0.02% | 1047 |
|
|
2020
Q4 | $11.8M | Sell |
769,977
-133,300
| -15% | -$1.56M | 0.01% | 1050 |
|
|
2020
Q3 | $10M | Sell |
903,277
-132,000
| -13% | -$1.55M | 0.01% | 1143 |
|
|
2020
Q2 | $13M | Buy |
1,035,277
+247,200
| +31% | +$3.15M | 0.01% | 1068 |
|
|
2020
Q1 | $8.94M | Buy |
788,077
+192,400
| +32% | +$2.74M | 0.01% | 1237 |
|
|
2019
Q4 | $7.81M | Buy |
595,677
+107,077
| +22% | +$1.13M | 0.01% | 1600 |
|
|
2019
Q3 | $4.4M | Buy |
488,600
+13,100
| +3% | +$124K | ﹤0.01% | 1867 |
|
|
2019
Q2 | $4.69M | Buy |
475,500
+3,200
| +0.7% | +$30.6K | ﹤0.01% | 1852 |
|
|
2019
Q1 | $4.8M | Sell |
472,300
-93,400
| -17% | -$792K | ﹤0.01% | 1837 |
|
|
2018
Q4 | $3.57M | Buy |
565,700
+38,363
| +7% | +$341K | ﹤0.01% | 1943 |
|
|
2018
Q3 | $6.96M | Buy |
527,337
+37,837
| +8% | +$438K | 0.01% | 1586 |
|
|
2018
Q2 | $4.5M | Buy |
489,500
+201,500
| +70% | +$1.25M | ﹤0.01% | 1853 |
|
|
2018
Q1 | $1.41M | Buy |
288,000
+39,000
| +16% | +$144K | ﹤0.01% | 2496 |
|
|
2017
Q4 | $703K | Buy |
249,000
+92,600
| +59% | +$252K | ﹤0.01% | 2801 |
|
|
2017
Q3 | $461K | Buy |
156,400
+26,100
| +20% | +$80.7K | ﹤0.01% | 2814 |
|
|
2017
Q2 | $410K | Sell |
130,300
-86,790
| -40% | -$339K | ﹤0.01% | 2818 |
|
|
2017
Q1 | $868K | Buy |
217,090
+102,890
| +90% | +$809K | ﹤0.01% | 2593 |
|
|
2016
Q4 | $879K | Buy |
114,200
+18,000
| +19% | +$145K | ﹤0.01% | 2592 |
|
|
2016
Q3 | $779K | Buy |
96,200
+47,700
| +98% | +$368K | ﹤0.01% | 2674 |
|
|
2016
Q2 | $286K | Buy |
48,500
+14,700
| +43% | +$101K | ﹤0.01% | 2950 |
|
|
2016
Q1 | $236K | Sell |
33,800
-5,305
| -14% | -$38.1K | ﹤0.01% | 3044 |
|
|
2015
Q4 | $314K | Buy |
39,105
+18,605
| +91% | +$159K | ﹤0.01% | 2869 |
|
|
2015
Q3 | $169K | Sell |
20,500
-21,500
| -51% | -$214K | ﹤0.01% | 2928 |
|
|
2015
Q2 | $484K | Buy |
+42,000
| New | +$581K | ﹤0.01% | 2731 |
|
Other funds holding XENE
ACA
DCM
PCH
Jim Simons's XENE Position: Q1 2026 in Review
Jim Simons opened a new position in Xenon Pharmaceuticals (XENE) in Q1 2026: 300,500 shares worth $17.5M. The stake represents 0.03% of the portfolio and ranks #712 among its holdings. This is a return to the name: Jim Simons previously reported a position in XENE as recently as Q3 2025.
Jim Simons first reported a position in XENE in Q2 2015 and has held it in 38 quarters since. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.
- Jim Simons held 300,500 shares of Xenon Pharmaceuticals worth $17.5M as of Q1 2026.
- Xenon Pharmaceuticals was a new Jim Simons position in Q1 2026.
- Xenon Pharmaceuticals made up 0.03% of Jim Simons's portfolio in Q1 2026, its #712 holding.
- Jim Simons first reported a position in Xenon Pharmaceuticals in Q2 2015 and has held it in 38 quarters since.
- 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.
Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.